Rocío Montejano

3.5k total citations
44 papers, 423 citations indexed

About

Rocío Montejano is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Rocío Montejano has authored 44 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 21 papers in Virology and 15 papers in Epidemiology. Recurrent topics in Rocío Montejano's work include HIV Research and Treatment (21 papers), HIV/AIDS drug development and treatment (17 papers) and HIV-related health complications and treatments (15 papers). Rocío Montejano is often cited by papers focused on HIV Research and Treatment (21 papers), HIV/AIDS drug development and treatment (17 papers) and HIV-related health complications and treatments (15 papers). Rocío Montejano collaborates with scholars based in Spain, France and Vietnam. Rocío Montejano's co-authors include José Ramón Arribas, Rosa de Miguel Buckley, Bernard Allaouchiche, Natalia Stella-Ascariz, José Ignacio Bernardino, Javier Rodríguez-Centeno, Julen Cadiñanos, Andrés Esteban-Cantos, Berta Rodés and José Manuel Sánchez‐Vizcaíno and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Rocío Montejano

41 papers receiving 413 citations

Peers

Rocío Montejano
Graeme Brendon Jacobs South Africa
Hyppolite K. Tchidjou Italy
Mauro Moroni Italy
Juan Delgado Spain
María Luisa Navarro Spain
Ilaria Izzo Italy
Michael R. Nelson United States
Christiana Smith United States
Rosa Dea Sperhacke Brazil
Alexandra Scherrer Switzerland
Graeme Brendon Jacobs South Africa
Rocío Montejano
Citations per year, relative to Rocío Montejano Rocío Montejano (= 1×) peers Graeme Brendon Jacobs

Countries citing papers authored by Rocío Montejano

Since Specialization
Citations

This map shows the geographic impact of Rocío Montejano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rocío Montejano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rocío Montejano more than expected).

Fields of papers citing papers by Rocío Montejano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rocío Montejano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rocío Montejano. The network helps show where Rocío Montejano may publish in the future.

Co-authorship network of co-authors of Rocío Montejano

This figure shows the co-authorship network connecting the top 25 collaborators of Rocío Montejano. A scholar is included among the top collaborators of Rocío Montejano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rocío Montejano. Rocío Montejano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Micán, Rafael, Rosa de Miguel Buckley, Lucía Serrano‐Luján, et al.. (2025). Three-Year Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide as a Switch Strategy in the Real World. Open Forum Infectious Diseases. 12(3). ofaf087–ofaf087. 1 indexed citations
3.
Payares‐Herrera, Concepción, Rosa Malo de Molina, Trinidad Martín-Donaire, et al.. (2024). Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial. Bone Marrow Transplantation. 59(6). 777–784. 5 indexed citations
4.
Buckley, Rosa de Miguel, Carmen Busca, Rafael Micán, et al.. (2024). Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV. HIV Medicine. 25(6). 684–691.
5.
Esteban-Cantos, Andrés, et al.. (2024). Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians. The Lancet HIV. 11(5). e333–e340. 8 indexed citations
6.
Marqués, María, Elena Múñez, Borja Quiroga, et al.. (2024). Strategies for prevention and treatment of SARS-COV-2 infection in patients with chronic kidney disease: Literature review. Nefrología (English Edition). 44(2). 150–158. 1 indexed citations
7.
Bernardino, José Ignacio, Belén Alejos, Javier Rodríguez-Centeno, et al.. (2023). Monocyte Activation and Ageing Biomarkers in the Development of Cardiovascular Ischaemic Events or Diabetes in People with HIV. Microorganisms. 11(7). 1818–1818. 2 indexed citations
8.
Busca, Carmen, Ángel Robles‐Marhuenda, Mariana Díaz‐Almirón, et al.. (2023). Prevalence and Temporal Trends of Autoimmune Diseases in People Living with HIV. AIDS Research and Human Retroviruses. 39(3). 130–135. 2 indexed citations
9.
Montejano, Rocío, et al.. (2023). The Current Mismatch Between COVID-19 Clinical Trial Design and the Evolving Profile of Hospitalized Patients: A Retrospective Cohort Analysis. Clinical Infectious Diseases. 78(4). 918–921. 1 indexed citations
10.
Ramírez, Margarita, Mar Masiá, Roger Paredes, et al.. (2023). Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses. BMC Infectious Diseases. 23(1). 286–286. 8 indexed citations
11.
Marcelo, Cristina, Lucía Serrano‐Luján, Carmen Busca, et al.. (2023). Epidemiological characteristic and prognosis changes in chronic hepatitis B in people living with HIV. Enfermedades infecciosas y microbiologia clinica (English ed ). 42(3). 130–134. 1 indexed citations
12.
Esteban-Cantos, Andrés, Javier Rodríguez-Centeno, Juan Carlos Silla-Castro, et al.. (2023). Effect of HIV infection and antiretroviral therapy initiation on genome-wide DNA methylation patterns. EBioMedicine. 88. 104434–104434. 14 indexed citations
13.
Díaz‐Almirón, Mariana, Carmen Busca, Rafael Micán, et al.. (2022). Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir‐based dual therapy. Bi‐lipid study. HIV Medicine. 24(5). 558–567. 2 indexed citations
14.
Buckley, Rosa de Miguel, Rocío Montejano, María Jiménez-González, et al.. (2022). Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance. Open Forum Infectious Diseases. 9(11). ofac610–ofac610. 7 indexed citations
15.
Martı́n-Carbonero, Luz, Rosa de Miguel Buckley, Lucía Serrano‐Luján, et al.. (2022). Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort. Enfermedades infecciosas y microbiologia clinica (English ed ). 40(3). 121–124. 1 indexed citations
16.
Díaz‐Menéndez, Marta, Fernando Calle, Rocío Montejano, et al.. (2022). Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure. Vaccine. 40(32). 4307–4311. 2 indexed citations
17.
Barasona, José Á., Estefanía Cadenas-Fernández, Sandra Barroso‐Arévalo, et al.. (2021). Safety of African Swine Fever Vaccine Candidate Lv17/WB/Rie1 in Wild Boar: Overdose and Repeated Doses. Frontiers in Immunology. 12. 761753–761753. 21 indexed citations
18.
19.
Montejano, Rocío, Rosa de Miguel Buckley, & José Ignacio Bernardino. (2019). Older HIV-infected adults: complex patients—comorbidity (I). European Geriatric Medicine. 10(2). 189–197. 5 indexed citations
20.
Troya, Jesús, Rocío Montejano, Pablo Ryan, et al.. (2018). Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study. PLoS ONE. 13(6). e0198768–e0198768. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Graeme Brendon Jacobs Breakdown of academic impact, for papers by Hyppolite K. Tchidjou Breakdown of academic impact, for papers by Mauro Moroni Breakdown of academic impact, for papers by Juan Delgado Breakdown of academic impact, for papers by María Luisa Navarro Breakdown of academic impact, for papers by Ilaria Izzo Breakdown of academic impact, for papers by Michael R. Nelson Breakdown of academic impact, for papers by Christiana Smith Breakdown of academic impact, for papers by Rosa Dea Sperhacke Breakdown of academic impact, for papers by Alexandra Scherrer
Rankless by CCL
2026